Look at DSW and most retailers, the winter kept shoppers inside, and most retailers bounced after the summer quarter numbers came in. This is a no brainer buy all the way, at least 5% profit.
bbby caters to populations that are better off in life; hence, only the weather would affect sales. Should be back to 80 shortly. Crammer is wrong, as usual, or contrarian.
now, do you believe the market is crooked? LOL. No one is telling us the truth. They bought and bashed at the same time.
Crammer along with other analysts bashed right before blowout Q2 results today. While they were buying, they bashed and drove the price down from 65 to 62 recently. I am quite sure the Q2 results were leaked.
Tourbillion ridiculous $1 price target, management silence, price driven down, 74 mil shares shorted---all part of the grand scheme to leave everyone, but inside loops, out of the game. This is a blockbuster game changer, don't mistake it for fat drug or some rare disease. Afrezza: insulin, tesla:cars
been catching the knife, I wish I had waited 2 months though, so I can get really cheap and load up like it is the last stock on the planet. I have to admit that I suck at timing.
back to $80 by next quarter.
access to movie libray which competes with nflx and redbox
access games, instead of paying $60 per game, now players can access games for $3-5 /day. reminds me of iTunes
access to cable TV, eliminates cable monthly ccharges (I hate comcast, Direct TV, Dish with a passion-- price gouching)
? Virtual glasses give 3D to gaming experience
The deal w sanofi is worth about $2 bil ( near a billion for upfront and milestones and another $1 bill sales/ commercial/reg). The question is, had they diluted 200 mil shares to get $2 billion, would that give them enough cash and chance to move forward and sale the company?
This deal, for next 2 years, sanofi is paying $2 bil, if they never see any profit. It seems like al Mann is buying a lot into sanofi expertise in sales/ commercialization. For sanofi, if they don't work their azzzs off, they might as well kiss $2 bill goodbye.
Sanofi only gets 65% if they profit, and al Mann can still sale the company to anyone else for full ( he only has to pay the $175 mil in loans)
But it has to pay back $175 mil loan from sanofi and it has to give sanofi first rights to counter offer. Huge incentive for sanofi to work hard to get that 65% profit sharing. This deal was to ensure a successful launch by the world's best diabetic drugs seller;hence, the large 65%. Al mann wants to see success, he doesn't care what happens now w the stock price. Buy all u can afford
do they serve two different functions or competing against one another?
there is a reason why AL Mann gave Sanofi 65% of the profit sharing; he wanted to see Sanofi push this for success. If you give your partner a huge percentage, they will push for success. If you give too little; they may slack off. I am with you on this estimate.
too obvious, nobody sells their shares like that. Just dump it in the open market and allow bidders to determine the price. Ridiculous!
My sense is that SNY is paying for all mnkd expenses. Initial was $150 mil, that is what they need to get the launch going, if expansion is needed, SNY will give more (the milestones). The $175 mil was just extra cash, so that was given as a loan which they have to pay back ONLY after they PROFIT. What an awesome deal. This is big bro helping little bro relationship, but big bro gets more at the end.
Buy all you can at this level; I am loading up to riches.
BTW, don't forget about technosphere, they may contract with other BP's to use this platform.
my question to you guys, why do they need the extra $175 mil? They already have $200 mil from their $40 mil remaining cash and 150 from Sanofi. What is the extra cash for?
yup! that is the misconception that people have; they think 65% is for mnkd but it is only for Afrezza. Mnkd still can make deals with other BPs for rights to use technosphere. When their intravenous or subcutaneous drugs run out of patents, they need to make new patents, Afrezza will be there for them. Example is Viagra at Pfizer, or in a competitive case they can take a subq/Iv drug and make it inhale version while in still in patent.
when this becomes public news, it will be in conjunction with other news such as advertisement and revenue guidance and so forth. It's gonna massively rally, they know it is heavily shorted and they know how to play this game.